Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

NORDIC BIOTECH K/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   1.1% 2.5% 3.7% 8.4% 1.7% 3.4% 19.0% 19.0%   Credit score (0-100)   85 62 50 28 71 54 7 7   Credit rating   A BBB BBB BB A BBB B B   Credit limit (kDKK)   3,263.8 0.3 0.0 0.0 28.9 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   13,167 0 0 0 0 0 0 0   Gross profit   13,005 -98.0 -119 -118 -133 -157 0.0 0.0   EBITDA   13,005 -98.0 -119 -118 -133 -157 0.0 0.0   EBIT   13,005 -1,354 -6,381 -118 -133 -157 0.0 0.0   Pre-tax profit (PTP)   12,997.0 -1,360.0 -6,387.0 -44,572.0 1,254.0 101,458.0 0.0 0.0   Net earnings   12,997.0 -1,360.0 -6,387.0 -44,572.0 1,254.0 101,458.0 0.0 0.0   Pre-tax profit without non-rec. items   12,997 -1,360 -6,387 -44,572 1,254 101,458 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   86,469 85,109 78,722 34,150 32,232 127,032 -254,208 -254,208   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 254,208 254,208   Balance sheet total (assets)   86,604 85,170 78,784 34,208 32,326 127,129 0.0 0.0   Net Debt   -1,036 -858 -734 -606 -7,190 -504 254,208 254,208     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   13,167 0 0 0 0 0 0 0   Net sales growth   0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   13,005 -98.0 -119 -118 -133 -157 0.0 0.0   Gross profit growth   0.0% 0.0% -21.4% 0.8% -12.7% -18.0% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   86,604 85,170 78,784 34,208 32,326 127,129 0 0   Balance sheet change%   17.7% -1.7% -7.5% -56.6% -5.5% 293.3% -100.0% 0.0%   Added value   13,005.0 -1,354.0 -6,381.0 -118.0 -133.0 -157.0 0.0 0.0   Added value %   98.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 -1.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 -1.0 -2.0 -3.0 -4.0 -5.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   98.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   98.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 1,381.6% 5,362.2% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   98.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   98.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   98.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   16.2% -1.6% -7.8% -78.9% 3.8% 127.3% 0.0% 0.0%   ROI %   16.3% -1.6% -7.8% -79.0% 3.8% 127.4% 0.0% 0.0%   ROE %   16.3% -1.6% -7.8% -79.0% 3.8% 127.4% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   99.8% 99.9% 99.9% 99.8% 99.7% 99.9% -100.0% -100.0%   Relative indebtedness %   1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   -6.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -8.0% 875.5% 616.8% 513.6% 5,406.0% 321.0% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   7.7 14.1 11.8 10.4 76.5 6.6 0.0 0.0   Current Ratio   7.7 14.1 11.8 10.4 76.5 6.6 0.0 0.0   Cash and cash equivalent   1,036.0 858.0 734.0 606.0 7,190.0 504.0 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   7.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   901.0 797.0 672.0 548.0 7,096.0 542.0 -127,104.0 -127,104.0   Net working capital %   6.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0